A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Neoplasms

In brief

To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.

Key facts

Study ID

NCT00057395

Run by

Aronex Pharmaceuticals

People needed

40

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid malignancies;
• Amenable to therapy with DACH platinum agents;
• Measurable disease (RECIST criteria);
• ECOG performance score of 0-2;
• Adequate hematopoietic, liver and renal function;
• Adequate cardiac function (maximum of class II, NYHA);
• Women of childbearing potential must have a negative urine or serum pregnancy test;
• Signed written informed consent;
• Subjects must be willing to be followed during the course of treatment/observation and follow-up.

You may not qualify if…

• No other active malignancies;
• No prior therapy with oxaliplatin;
• No known brain metastases;
• Active, uncontrolled infection or other serious medical illnesses;
• Not using or have used any investigational therapy during four weeks before start of protocol treatment.

Where it is running

• John Wayne Cancer Institute — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.